$13.51
+2.2%Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Chief Executive Officer & Director
Compensation
$1,361,350
Executive Chairman
Compensation
$347,500
Executive Vice President & Chief Financial Officer
Compensation
$871,889
Executive Vice President & Chief Human Resources Officer
Executive Vice President & Chief Strategy Officer
Compensation
$616,042
Executive Vice President and Chief Administrative & Development Officer
Compensation
$819,104
General Counsel & Senior Vice President
President of National Group
Compensation
$681,350
Senior Vice President & Chief Compliance Officer
Senior Vice President of Corporate Finance & Controller
During the last 12 months, insiders have sold $1.41M worth of SGRY shares, with no buying activity reported.
0
0.00
95.1K
1.26M
-1.3M
-$1.26M
0
0.00
1.8K
24.86K
-25K
-$25K
0
0.00
0
0.00
+0
+$0
0
0.00
5.7K
128.72K
-129K
-$129K
No buying activity
Evans Jason Eric
Officer: Chief Executive Officer
$412K
Doherty David T
Officer: Chief Financial Officer
$313K
Baldock Jennifer
Officer: Chief Admin & Dev Officer
$214K
Brittenham Marissa
Officer: Chief Strategy Officer
$166K
Burkhalter Danielle
Officer: Chief Human Resources Officer
$150K
Strong bearish signal with $1.41M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SGRY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 06, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 20, 2023 | April 20, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | May 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 15, 2021 | May 26, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 17, 2020 | May 27, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | May 29, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 19, 2018 | May 04, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 17, 2017 | May 02, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.